Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statements of Operations (Unaudited)

v3.19.3
Condensed Consolidated Interim Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Expenses    
Research and development $ 721,475 $ 1,019,120
General and administrative 913,628 986,470
Operating expenses 1,635,103 2,005,590
Other (income) loss    
Change in fair value of derivative liability 220
Foreign exchange (gain) loss (374) 5,838
Interest income (28,858) (19,844)
Other loss (income) (29,232) (13,786)
Net loss for the period 1,605,871 1,991,804
Computation of basic loss per share    
Net loss for the period 1,605,871 1,991,804
Series B Preferred stock dividend 2,046 36,085
Net loss for the period attributable to common stockholders $ 1,607,917 $ 2,027,889
Basic and fully diluted loss per share $ 0.21 $ 0.88
Basic weighted average number of shares 7,538,562 2,296,909